UNSPSC 51311607: Mepyramine maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H23N3O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R35D29L3ZA, chemically known as n-(p-methoxybenzyl)-n, n-dimethyl-n-.alpha.-pyridylethylenediamine maleate but more generally known as mepyramine maleate, which bears US NIH Compound Identifier 5284451. European Medicines Agency schedules Mepyramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14516MIG.

Most nations, for tariff and trade purposes, schedule mepyramine maleate under HS 29333999. SMILES: CN(C)CCN(CC1CCC(CC1)OC)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51311607 Mepyramine maleate is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and systems procured for community health, emergency response, and pharmacy benefit programs. The opportunities tagged to this code show state and local governments buying naloxone and drug deactivation systems for health department distribution, generic multi-source pharmaceuticals and OTC products through cooperative purchasing alliances, and exploring direct-to-manufacturer prescription fulfillment models. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The work spans procurement of finished pharmaceutical products for distribution networks, establishment of supply contracts with wholesalers and manufacturers, and market intelligence gathering on alternative pharmacy benefit delivery models.

Recent activity concentrates in Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products available through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors responding must meet FDA compliance, cGMP certification, Drug Supply Chain Security Act requirements, and maintain specified insurance coverage; MMCAP applies a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.